Welcome to LookChem.com Sign In|Join Free

CAS

  • or

144261-17-6

Post Buying Request

144261-17-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

144261-17-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 144261-17-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,4,2,6 and 1 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 144261-17:
(8*1)+(7*4)+(6*4)+(5*2)+(4*6)+(3*1)+(2*1)+(1*7)=106
106 % 10 = 6
So 144261-17-6 is a valid CAS Registry Number.

144261-17-6Relevant articles and documents

H2 cleavage, hydride formation, and catalytic hydrogenation of imines with zinc complexes of C5Me5 and N-heterocyclic carbenes

Jochmann, Phillip,Stephan, Douglas W.

, p. 9831 - 9835 (2013)

Decamethylzincocene, [ZnCp2], reacts with H2 to give the reduced ZnI compound [Zn2Cp2]. In the presence of coordinating and (more efficiently) of non-coordinating N-heterocyclic carbenes (NHCs), the catalytic hydrogenation of imines with H2 is achieved. The monomeric hydride [Zn(Cp)(H)(SIMes)] is presented and its mechanistic implications are considered. Copyright

Structure-Activity Relationship and Biological Investigation of SR18292 (16), a Suppressor of Glucagon-Induced Glucose Production

Cameron, Michael D.,Griffin, Patrick R.,Kamenecka, Theodore M.,Lin, Hua,Lin, Li,Novick, Scott J.,Puigserver, Pere,Ruiz, Claudia,Sharabi, Kfir,Zhu, Di

supporting information, p. 980 - 990 (2021/02/01)

Despite a myriad of available pharmacotherapies for the treatment of type 2 diabetes (T2D), challenges still exist in achieving glycemic control. Several novel glucose-lowering strategies are currently under clinical investigation, highlighting the need f

2,4-SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS

-

Page/Page column 69, (2010/10/20)

Substituted heteroaryl nitrile derivatives of Formula (I) processes for their preparation, pharmaceutical compositions comprising such compounds and use of the compounds as cysteine protease inhibitors are provided.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 144261-17-6